TY - JOUR T1 - Influence of Novel Coronavirus COVID – 19 and HIV: A Scoping Review of Hospital Course and Symptomatology JF - medRxiv DO - 10.1101/2021.07.25.21260967 SP - 2021.07.25.21260967 AU - Mona Sheikh AU - Shavy Nagpal AU - Madiha Zaidi AU - Rupalakshmi Vijayan AU - Wanessa Matos AU - Neguemadji Nagardig Ngaba AU - Lordstrong Akano AU - Samia Jahan AU - Shazia Q. Shah AU - Camille Celeste Go AU - Sindhu Thevuthasan AU - George Michel Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/28/2021.07.25.21260967.abstract N2 - Background An outbreak of novel coronavirus (SARS- CoV-2) was observed on December 2019 in Wuhan, China which led to a global pandemic declared in March 2020. As a consequence, it imposed delirious consequences in patients with underlying co – morbid conditions that make them immunocompromised. The purpose of this paper is to provide an in - depth review of influence of COVID – 19 in patients with underlying HIV in terms of mortality and hospitalization.Authors also aim to provide a thorough risk analysis of hospitalization, ICU admission and mortality of PLWH and COVID-19. The secondary objective was to analyze the CD4+ count variations and outcome of COVID - 19 and to correlate if ART provided a protective role. Authors also aim to provide an evaluation of typical clinical presentation of COVID-19 in PLWH. ART is found to show activity against SARS-CoV-2 in vitro, and there is some similarity in the structure of HIV-1 gp41 and S2 proteins of SARS-CoV since they both belong to +ssRNA type.Methods We conducted a literature review using search engines namely, Cochrane, PubMed and Google Scholar. The following keywords were targeted: “COVID-19,” “SARS-CoV-2,” and “HIV.” We included case reports, case series, and cohort (retrospective and prospective) studies. We excluded clinical trials and review articles. We came across 23 articles that met the inclusion criteria. PRISMA guidelines were followed for study acquisition (Fig. 9).Results From the 23 studies, we found a total of 651 PLWH with confirmed COVID-19 (549, 91, and 11 in cohorts, case series, and case reports, respectively). The overall risk of hospital admission from pooled data of the 23 reviewed articles was 69.13% (450/651), ICU admission was 12.90% (84/651) in total infected patients, and 18.67% (84/450) among hospitalized patients. The overall case fatality rate from the 23 reviewed articles was 11.21 (73/651).A weak positive correlation was found between CD4+ counts and hospital admissions in case series and case reports, while the weak negative correlation was found in cohorts. For mortality, there was a negative weak association in the cohorts and in case series, while a weak positive was seen in case reports (Fig.7). We assessed the presenting symptoms of PLWH with COVID-19, and our review demonstrated this group does not greatly differ from the rest of the population, as their common presenting symptoms were cough, fever, and SOB.Conclusion Our results indicated that there was a high rate of hospitalization, ICU admission, and mortality among patients living with HIV and COVID-19. PLWH needs to be noted as a high-risk group for COVID-19 complications and severity. We recommend that PLWH be closely monitored by their physicians and strictly adhere to antiretroviral therapy and standard universal COVID-19 precautions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThere is no financial disclosure related to this study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We did not seek IRB approval, as our study is based on data from published articles and patients were not directly involved.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesA literature search was conducted with PubMed, Cochrane, and Google scholars using the following keywords: COVID-19, HIV, SARS-CoV-2, and AIDS from January 2020 until August 31st, 2020. Only papers in English language were considered. PRISMA guidelines were followed (Fig. 9)HIVHuman immunodeficiency virusARTAntiretroviral therapyICUIntensive care unitPLWHPeople living with HIV+ssRNApositive single stranded RNASOBshortness of breathHTNhypertensionDMdiabetes mellitusCKDchronic kidney diseaseCOPDchronic obstructive pulmonary diseaseCVDcardiovascular diseaseHLDhyperlipidemiaHBVhepatitis B virusHCVhepatitis C virusCADcoronary artery diseaseESRDend stage renal diseaseNASHnon-alcoholic steatohepatitisOSAobstructive sleep apneaCHFcongestive heart failureTBtuberculosis ER -